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When ligaments such as the medial collateral ligament (MCL) are injured, they generally 
heal but form scar tissue, which is composed of a disorganized collagen matrix that is over-
produced by fibroblasts.  Scar tissue has inferior structural and mechanical properties, which can 
lead to joint instability. Excessive fibroblast contraction is thought to contribute to tissue 
scarring.  Previous studies have shown that both TGF-β1 and TGF-β3 increase fibroblast 
contraction and collagen synthesis.  However, TGF-β1 enhances scar tissue formation whereas 
TGF-β3 actually reduces it.  In addition, both TGF-β isoforms have been found to increase the 
expression of α-SMA, which correlates with increased fibroblast contractility.  An increase in 
tension at the wound site has also been found to increase α-SMA protein levels.  Therefore these 
factors are all important in the wound healing process.  The overall objective of this thesis 
research was to investigate cellular and molecular mechanisms that affect scar tissue formation 
in healing ligaments.  Contraction forces, collagen synthesis, and α-SMA protein expression of 
healing and normal MCL fibroblasts in response to treatment with TGF-β1, TGF-β3, and 
collagen gel tension were investigated.  A novel culture force monitor (CFM) system was used to 
quantify forces of fibroblast contraction.  It was found that healing MCL fibroblasts produced 
 
iii
greater contractile forces and higher levels of collagen synthesis than normal MCL fibroblasts.  
In addition, treatment with TGF-β1 or TGF-β3 increased contraction forces in healing fibroblasts 
compared to untreated controls, with TGF-β1 consistently producing greater contraction forces 
than treatment with TGF-β3. TGF-β1 and TGF-β3 also induced higher levels of α-SMA protein 
expression compared to untreated fibroblasts.  Consistent with the contraction forces, fibroblasts 
treated with TGF-β1 expressed higher levels of α-SMA protein than those treated with TGF-β3.  
Further, it was found that when tension in gels embedded with normal MCL fibroblasts was 
released, expression of α-SMA protein also decreased.  Thus, this study showed that healing and 
normal fibroblasts have differential contractile and collagen synthesis abilities.  The results of 
this study showed that the presence of TGF-β1, TGF-β3, and tension in the matrix should be 
regulated to improve ligament healing.  Decreasing the ratio of TGF-β1 to TGF-β3 in an injured 
ligament may decrease fibroblast contraction and thus reduce scar formation in healing MCLs.  
Finally, reducing tension levels in healing ligaments and hence down-regulating α-SMA protein 
expression may also decrease ligament scarring.  
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1.0  INTRODUCTION 
 
 
 
Many sports injuries involve the rupture of the medial collateral ligament (MCL) [1], which 
plays an essential role in stability of the knee [2, 3].  Although treatment of an injured MCL is 
most often conservative [4, 5], i.e. non-surgical with a period of immobilization, the ligament 
tends to heal with formation of scar tissue [3, 6], which can cause inferior structural and 
mechanical properties [2, 3].  While a normal ligament has fibroblasts that are aligned with 
collagen fibers along the longitudinal axis of the ligament, the healed ligament has a 
disorganized and overproduced collagen matrix, which is characteristic of scar tissue [7].  
Therefore, in order to better understand the cellular and molecular mechanisms involved in the 
wound healing process, it is important to first investigate the differences between cells from a 
healing environment and cells from a normal environment.   
 
In addition to collagen synthesis, excessive contractile forces are thought to contribute to the 
formation of scar tissue [8, 9].  Growth factor isoforms transforming growth factor (TGF)-β1 and 
TGF-β3 have been shown to increase cell contraction and collagen synthesis [10-13].  However, 
in rat skin wounds, exogenous addition of TGF-β3 was found to decrease scar formation, 
whereas TGF-β1 increased the formation of scar tissue [14].  In addition, TGF-β1 and TGF-β3 
both increase the expression of α-smooth muscle actin (SMA), which correlates to an increase in 
fibroblast contraction [15-18].  Further, tension in the matrix also regulates α-SMA expression, 
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with increased tension increasing α-SMA expression [19, 20].  Therefore, quantifying the 
differences between fibroblasts in a healing ligament to those from an uninjured ligament may 
help to elucidate mechanisms involved in ligament scarring.  Regulating the ratio of TGF-β1 to 
TGF-β3 or altering the tension in a healing matrix may help to decrease scar tissue formation and 
therefore, improve the function of injured ligaments.  Thus, the overall goal of this thesis was to 
investigate the cellular and molecular mechanisms involved in scar formation in healing 
ligaments.  To this end, we first looked into the possible differences in function, i.e. contraction 
and collagen synthesis, between healing and normal MCL fibroblasts and then investigated the 
regulation of α-SMA and cell contraction by TGF-β1, TGF-β3, and gel tension. 
 
This thesis is organized as follows.  The next chapter (Chapter 2) is a review of previous 
studies and literature on the following topics: tissue wound healing, transforming growth factor-
β, α-smooth muscle actin, and tension vs. α-SMA.  Chapter 3 discusses the specific aims of this 
thesis and provides a hypothesis from each aim.  The subsequent chapters discuss each aim in 
further detail.  Chapter 4 investigates the differences in contraction and collagen synthesis 
between fibroblasts from a healing MCL and those from a normal, uninjured MCL.  In chapter 5, 
the effects of TGF-β1 and TGF-β3 on fibroblast contraction and α-SMA protein expression of 
healing fibroblasts were investigated.  Chapter 6 focuses on the effect of relaxation of tensioned 
collagen gels seeded with normal MCL fibroblasts on α-SMA expression.  Finally, chapter 7 
provides a summary of the findings from this thesis study and discusses future research 
directions.   
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2.0  LITERATURE REVIEW 
 
 
 
2.1 TISSUE WOUND HEALING 
 
 
Injuries to the MCL have been shown to heal without surgical intervention [4, 5].  However, the 
healed ligament has inferior mechanical properties in comparison to uninjured tissue, even at one 
year post-injury [2, 3, 21].  The altered structural composition of the scar tissue that forms after 
injury hinders the ligament from functioning as a normal ligament does.  Injured MCLs have 
been shown to have a cross-sectional size almost twice that of the sham control [2, 22] as well as 
greater laxity in the ligament [2, 3], which leads to an increase in rotation of the knee [4].  Thus, 
scarring of the injured MCL causes impaired function of the ligament.   
 
Scar tissue is thought to form from excessive collagen production and contraction at the 
wound site [7, 8, 23].  While some contraction is necessary for wound closure, excessive 
contraction may contribute to the inferior quality of the healed ligament.  Studies have found 
that, unlike adult wounds, fetal wounds tend to heal without scar formation [8, 24-26].  This 
differential healing process may be caused by the different levels of growth factors, such as 
TGF-β1 and TGF-β3, found in fetal wounds as compared to adult wounds [24, 27-29].  TGF-β1 
and TGF-β3 have both been found to increase cell contraction and collagen synthesis [10-13].  
However, in rat skin wounds, TGF-β3 decreased scar formation, whereas TGF-β1 actually 
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increased it [14].  Interestingly, both TGF-β1 and TGF-β3 increase α-SMA protein expression in 
fibroblasts as well [15-18].  Increased contraction of fibroblasts has been attributed to an increase 
in α-SMA expression [18, 30].  Expression of α-SMA is also increased by increased tension at 
the wound site [19], such as during wound closure [16].  This increase in α-SMA expression may 
signify the presence of myofibroblasts in the healing environment, which are specialized cells 
that are known to produce increased contractile forces in the healing environment [31].  
Therefore, regulating the factors that increase α-SMA, such as TGF-β1, TGF-β3, and tension in 
the matrix, may decrease contraction forces, in the healing environment and help to restore the 
biochemical and biomechanical properties of an uninjured ligament. 
 
 
 
2.2 TRANSFORMING GROWTH FACTOR-β (TGF- β) 
 
 
In general, there are four distinct stages in the healing process: inflammation, formation of 
granulation tissue, deposition of new extracellular matrix (ECM), and remodeling.  During the 
inflammatory stage, neutrophils and macrophages invade the wound area and remove cellular 
debris and pathogens from the injured tissue [32].  Following this stage, platelets and other 
immunological cells begin to secrete TGF-β [29, 33], which stops the inflammatory response.  
This growth factor stimulates fibroblasts to produce collagens [10, 13, 33] and induces fibroblast 
contraction, which are both necessary for wound healing and closure. 
As mentioned previously, the transforming growth factor (TGF)-β family has been 
implicated in the wound healing process [18].  TGF-β has five known isoforms, the active forms 
of which are disulfide-linked homodimers.  Consisting of 390 amino acids, TGF-β1 maps to 
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human chromosome 19q13 (www.grt.kyushu-u.ac.jp/spad/account/ligand/tgf-beta.html).  
Activation of TGF-β1 occurs through TGF-β receptors I and II, which are transmembrane 
serine/threonine kinases [34-36].  Smad proteins 3, 6, and 7 may all be important in the 
regulation of receptors I and II.  Using microarray analysis, it was shown that 95% of the gene 
targets of TGF-β are dependent on Smad3 [37].  The same study demonstrated that embryonic 
fibroblasts from mice lacking the expression of Smad3 did not contract with the addition of 
TGF-β1, while the same cells from mice expressing this protein were contractile [37].  In the 
presence of TGF-β itself, Smad6 and Smad7 inhibited signals from TGF-β receptors, giving 
them a regulatory control over production and secretion of this growth factor [36].  Although 
TGF-β1 is found largely in platelets, it can also be produced by other types of cells, such as 
activated macrophages, neutrophils, fibroblasts, and keratinocytes [35]. 
 
Another isoform of TGF-β is TGF-β3, which was characterized much after TGF-β1 in the 
late 1980s.  The human form of TGF-β3 is a polypeptide that is 410 amino acids in length [38] 
with a highly conserved C-terminal region [39].  Although there is a lot of sequence homology 
between TGF-β1 and TGF-β3, two of the major differences are the number of potential N-
glycosylation sites and the number of cysteine residues [38, 39].  While TGF-β1 has only three 
N-glycosylation sites, TGF-β3 has four.  In addition, TGF-β3 has a total of five cysteine 
residues, which is one more than TGF-β1 [38].  These two isoforms are also differentially 
expressed in tissues in the body.  Adult wounds contain greater amounts of TGF-β1 compared to 
TGF-β3, whereas fetal wounds have a higher ratio of TGF-β3 to TGF-β1 [24, 27-29]. 
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TGF-β1 plays a large role in wound healing.  It is secreted by platelets at the injury site and 
aids in extracellular matrix deposition among other things [34, 36].  Over-expression of TGF-β1 
can result in tissue fibrosis, not only in the skin, but also in the liver and kidney [36].  In 
particular, TGF-β1 increases cellular contraction, as well as collagen synthesis in fibroblasts [11-
13], both of which contribute to the formation of scar tissue [7-9].  TGF-β1 increases fibroblast 
contraction in a dosage-dependent manner, but exceedingly high concentrations induce lower 
increases in contraction [11].   
 
Furthermore, TGF-β1 has also been found to increase α-SMA expression [15-17, 40], which 
is a marker of myofibroblasts [17, 19, 30, 41].  This growth factor further promotes fibroblast 
differentiation by increasing the presence of other structural features of myofibroblasts, such as 
stress fibers, fibronexus adhesion complexes, and fibronectin fibrils [42].  Interestingly, while 
TGF-β1 is present in abundance in adult tissues, only small amounts are present in fetal tissue 
[27-29, 43, 44].  Contrastingly, TGF-β3 is much more abundant in fetal tissues than in adult 
tissues, which may largely contributes to the differential scar formation that occurs between fetal 
and adult wounds.  TGF-β1 has been shown to increase scar formation in rat skin wounds and 
anti-TGF-β1 agents have been shown to improve healing by decreasing scar formation [14, 45].  
Further, in a rabbit model, scarring was decreased in wounded eyes treated with TGF-β1 
antisense oligonucleotides [46].  Therefore, regulation of TGF-β1 has been shown to improve 
healing in many different wound healing models. 
 
Functionally similar to TGF-β1, TGF-β3 has also been found to affect biological functions of 
cells, such as cell contraction and collagen synthesis [10, 11, 18, 29, 47].  Interestingly, studies 
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investigating the potency of TGF-β3 on cell contraction in collagen gels differ in their results.  
Some studies show that TGF-β3 induces greater contractile ability in AKR-2B fibroblasts, fetal 
and adult skin fibroblasts, as compared to TGF-β1 [18, 47] while others show that TGF-β3 is less 
potent than TGF-β1 in adult skin and patellar tendon fibroblasts [11, 12].  TGF-β3 also affects α-
SMA expression in both adult and fetal skin fibroblasts [18].  Moulin et al. found that without 
any growth factor treatment, α-SMA expression was higher in fetal fibroblasts as compared to 
adult fibroblasts [18].  However, after treatment with TGF-β3, there was a significant increase in 
the expression of α-SMA in adult skin fibroblasts but not in fetal skin fibroblasts.  Further, fetal 
wounds heal without scar formation [8, 24-26].  In addition, in rat skin wounds, exogenous 
addition of TGF-β3 or neutralization of TGF-β1 actually decreased the formation of scar tissue 
[14, 48].  Therefore, treatment with TGF-β3 may increase levels of fibroblast contraction and α-
SMA expression to those essential for proper wound healing, without scar formation. 
 
The findings of these studies suggest that TGF-β1 and TGF-β3 are both important in the 
wound healing process.  Both TGF-β1 and TGF-β3 have been found to affect many biological 
functions of cells, such as cell contraction and α-SMA expression.  Although these isoforms have 
similar functions, they have a differential effect on scar formation in wounded skin.  Therefore, 
to reduce scarring in injured ligaments such as MCLs, TGF-β1 and TGF-β3 may need to be 
differentially regulated.   
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2.3 α-SMOOTH MUSCLE ACTIN (α-SMA) 
 
 
Expression of α-SMA is an important factor in the wound healing process.  This protein appears 
as stress fibers in fibroblasts and often results in increased contractile forces of the cells [31].  α-
SMA consists of 19 amino acids and has a molecular weight of 42 kDa [49].  Similar to α-SMA, 
β-actin is another actin isoform, which is expressed in all eukaryotic cells and has the same 
molecular weight.  However, β-actin expression is generally constant as it is essential for cell 
functions, such as cell motility and growth [50].   
 
α-SMA is a specific marker of specialized cells called myofibroblasts [17, 19, 30, 41].  
Myofibroblasts are hybrid cells with properties of both fibroblasts and smooth muscle cells [8, 
30, 31].  Many studies have shown that myofibroblasts are only transiently present in wound 
sites during wound healing [30, 40, 41, 51], i.e. they disappear once the wound is closed and scar 
tissue is formed.  For example, a previous study showed that myofibroblasts were not present at 
the beginning of the healing process [30].  However, by day 14, they were abundant and by day 
30 had disappeared again.  Further, in fetal sheep skin tissue, an excisional wound healed without 
scar formation when α-SMA positive cells were absent [24].  However, when α-SMA positive 
cells began to appear, there was an increase in both cell contraction and scar formation. 
 
The expression of α-SMA is regulated by many factors, such as growth factors, i.e. TGF-β, 
and tension on tissues.  Growth factor isoforms TGF-β1 and TGF-β3 have been found to increase 
protein expression of α-SMA [15-18, 40, 52], as was discussed in the Transforming Growth 
Factor-β section.  In addition, it was found that in rats where α-SMA protein expression had 
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been inhibited by vanadate, skin wounds healed with marked improvement of scarring [53].  
There was no evidence of α-SMA at the wound site and the collagen fibers were neatly 
organized in the healed area, i.e. no scar formation.  Thus, the presence of α-SMA may hinder 
proper healing.   
 
 
 
2.4 TENSION VS. α-SMA EXPRESSION 
 
 
As with α-SMA expression, the presence of tension in healing tissue also has a significant impact 
on the healing process.  It can alter the expression of many proteins in the matrix, which can 
thereby affect the repair or regeneration of the wound tissue.  In vitro, tension in a collagen 
matrix embedded with cells can be produced by anchoring collagen gels at the sides or bottom.  
This model mimics the wound healing environment much better than free floating collagen gels 
because wound closure creates tension in the healing matrix.  In comparing this stressed model 
(e.g., anchored collagen gel) to unstressed models (e.g., floating collagen gel), several studies 
have found differential protein expression.  Skin fibroblasts showed higher total protein 
synthesis, in particular elevated collagen expression, in stressed collagen gels [54].  Tension can 
be induced in matrices both intracellularly and extracellularly.  When cells contract, they move 
through the intertwined collagen matrix and elongate themselves [55], creating intracellular 
tension.  Extracellular tension can be added to the matrix by applying forces to the matrix.  It was 
found that in matrices with high tension, i.e. collagen coated plastic, α-SMA protein expression 
of gingival fibroblasts was increased about 9 fold compared to matrices without tension, i.e. free 
9 
 
  
 
 
floating collagen gels [19].  Further, when mechanical tension was induced in a skin wound by 
splinting the wound, α-SMA protein expression was increased by 420% [20].   
 
Tension in the matrix has also been linked to the differentiation of fibroblasts into 
myofibroblasts [19, 20, 56].  The increase in α-SMA caused by increased tension may contribute 
to this differentiation.  It has been shown that tension induces α-SMA expression in rat skin 
wounds [20].  However, when tension was released from rat skin wounds, expression of α-SMA 
and ED-A fibronectin, another marker for myofibroblasts, decreased [20].  In cardiac fibroblasts, 
cells with low basal levels of α-SMA showed up to a 2 fold increase in α-SMA protein 
expression with the application of an extracellular force [57].  Thus, both in vivo and in vitro, 
tension was found to affect the level of α-SMA expression and myofibroblast differentiation.  
Therefore, regulation of tension in the matrix may reduce scar formation in healing tissues such 
as ligaments. 
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3.0  SPECIFIC AIMS OF THESIS 
 
 
 
 
Although the MCL tends to heal, it does so with the formation of scar tissue [3, 6].  Because of 
its inferior mechanical properties, scar tissue in the healing MCL can result in a decrease in the 
stability of the knee joint due to increased laxity [2, 3].  Therefore, it is necessary to reduce 
scarring in healing MCLs by regulating those factors that contribute to the formation of scar 
tissue, including excessive fibroblast contraction and collagen production [7-9].  Differentiation 
of fibroblasts into myofibroblasts at the wound site may also contribute to inferior healing, by 
increasing contractile forces and scar formation [53].  Myofibroblasts are known to increase 
contraction at the wound site [20], and are marked by the presence of α-SMA [17, 19, 30, 41, 
52].  TGF-β1 and TGF-β3 have both been found to regulate fibroblast contraction and collagen 
synthesis, as well as α-SMA expression in vitro in fibroblasts.  Interestingly, TGF-β3 has been 
found to decrease scar formation in rat skin wounds, whereas TGF-β1 increases scarring [14].  
The application of tension to skin wounds by splinting the wound also increases α-SMA 
expression [20], which may indicate an increase in the presence of myofibroblasts.  Although 
many studies have investigated the regulation of growth factors and tension in skin wounds, few 
have investigated their role in ligament healing.  Therefore, the overall objective of this study 
was to investigate the cellular and molecular mechanisms involved in ligament healing that may 
contribute to scar tissue formation. 
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3.1  SPECIFIC AIM 1 
 
 
To determine the differential contraction and collagen synthesis of healing vs. normal rat MCL 
fibroblasts.  While normal fibroblasts simply maintain the matrix, healing fibroblasts need to 
repair and regenerate the matrix of injured tissue.  Fibroblast contraction and collagen synthesis 
are both necessary to regenerate the matrix in healing ligaments.  Contraction and collagen 
synthesis are up-regulated in keloid skin fibroblasts compared to normal fibroblasts [58, 59].  
Therefore, it is likely that healing ligament fibroblasts also produce higher levels of contraction 
and more collagen than normal fibroblasts.  
 
Hypothesis 1: Healing fibroblasts generate larger contraction forces and produce 
more collagen type I than normal fibroblasts. 
12 
 
  
 
 
 
 
 
3.2  SPECIFIC AIM 2 
 
 
To determine the effects of TGF-β1 and TGF-β3 on fibroblast contraction and α-SMA 
expression of healing fibroblasts.  TGF-β1 and TGF-β3 have both been found to increase 
fibroblast contraction and α-SMA protein expression in vitro [11, 12, 15, 18, 42].  However, in 
skin and tendon fibroblasts, TGF-β1 increases contraction to a greater degree than TGF-β3 [11, 
12].  TGF-β1 mRNA levels were also greater in hypertrophic scar fibroblasts as compared to 
normal dermal fibroblasts [60].  Further, TGF-β3 has been found to reduce scarring in skin 
wounds, whereas TGF-β1 increases it [14].  Therefore, TGF-β1 and TGF-β3 differentially 
regulate fibroblast contraction and α-SMA protein expression. 
  
Hypothesis 2a: TGF-β1 and TGF-β3 induce greater contraction forces and greater 
α-SMA protein expression in healing fibroblasts compared to 
untreated fibroblasts. 
 
Hypothesis 2b: TGF-β1 induces greater contraction forces and α-SMA protein 
expression in healing fibroblasts than TGF-β3. 
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3.3  SPECIFIC AIM 3 
 
 
To determine the effect of gel tension on α-SMA protein expression in normal rat MCL 
fibroblasts.  Previous studies have shown that fibroblasts in matrices under greater extracellular 
tension expressed higher α-SMA protein levels [19].  Further, tensioning skin wounds by adding 
a splint under them induced greater α-SMA protein expression than their released counterparts 
[20].  Transiently expressed during tissue wound healing [30, 41], α-SMA protein is a marker of 
myofibroblasts, which and are known to produce increased contractile forces [20].  Therefore, 
decreasing the level of tension in the matrix may also decrease α-SMA protein expression. 
 
Hypothesis 3: Reducing tension in fibroblast populated collagen gels (FPCGs) 
decreases α-SMA protein expression. 
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This thesis first investigated the differences in contraction and collagen synthesis between 
healing and normal ligament fibroblasts and then looked into the effects of TGF-β1, TGF-β3, 
and tension on these cells.  Both excessive fibroblast contraction and collagen synthesis are 
major factors in the formation of scar tissue.  Tension in the matrix, TGF-β1, and TGF-β3 are 
known to increase expression of α-SMA, which may contribute to the increase in fibroblast 
contractility during healing.  The findings of this thesis will aid in better understanding the 
cellular and molecular mechanisms of tissue scarring. 
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4.0  CONTRACTION AND COLLAGEN SYNTHESIS OF HEALING VS NORMAL 
RAT MCL FIBROBLASTS 
 
 
 
4.1 ABSTRACT 
 
 
Fibroblasts from a healing ligament must have differential expression from those in an intact 
ligament, because they must be able to regenerate the wounded matrix around them caused by 
injury.  The purpose of this study was to investigate the differences in contraction forces and 
collagen synthesis between fibroblasts from a healing ligament and those from an intact/normal 
ligament, since both excessive contraction and increased collagen synthesis have been implicated 
in the formation of scar tissue.  The formation of scar tissue at the site of injury in a ligament 
may contribute to the inferior structural and mechanical properties of the injured ligament.  
When seeded in collagen gels, healing fibroblasts were found to generate 1.6 and 1.7 fold greater 
contraction forces at 15 and 20 hours, respectively, compared to normal fibroblasts.  Further, 
healing fibroblasts produced 10% more type I collagen than normal fibroblasts.  Taken together, 
these results show that healing fibroblasts have a different phenotype than normal fibroblasts.  
This study also highlights the importance of using healing fibroblasts to study the cellular and 
molecular mechanisms of ligament healing. 
16 
 
  
 
 
4.2 INTRODUCTION 
 
 
The MCL is injured frequently during sports activities [1].  Although it has been found to heal 
sufficiently with conservative treatment, i.e. without surgery but with immobilization of the knee 
[4, 5], the healing process results in formation of scar tissue [3, 6].  Excessive collagen 
production as well as excessive contraction forces exerted by cells at the wound site both 
contribute to this scar formation [7, 8].  The increased contraction and collagen synthesis cause 
the matrix at the wound site of an injured MCL to be highly disorganized and the fibroblasts do 
not align along any one direction [6].  While fibroblasts in the healing process repair and 
remodel the wounded tissue, those from normal tissue simply maintain the matrix around them.  
Therefore, healing and normal fibroblasts may exhibit differences in function, such as 
contraction and collagen synthesis.  Identifying the differences between healing and normal 
fibroblasts responsible for these different functions can provide insight into the cellular and 
molecular mechanisms of tissue wound healing, and therefore aid in devising new therapeutic 
strategies to enhance the quality of healing tissues. 
 
Previous studies have shown that cells from a healing environment produce increased 
amounts of collagen and TGF-β1 [59, 61, 62].  In a study comparing peripheral blood 
mononuclear cells (PBMCs) from burn patients to those from normal individuals, it was found 
that the cells from the burn patients produced greater amounts of collagen [62].  Similarly, 
fibroblasts from hypertrophic scars secreted more type I collagen than normal dermal fibroblasts 
[60].  Keloid fibroblasts also secreted a significantly larger amount of TGF-β1 compared to 
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normal skin fibroblasts [61].  Healing fibroblasts need to contract more than normal cells in order 
to close the wound quickly as well as produce more collagen for the formation of the healed 
tissue.  TGF-β1 has been found to regulate both collagen production as well as contraction forces 
of fibroblasts [11-13, 63].  Therefore, a greater presence of TGF-β1 at the wound site may 
largely contribute to the formation of scar tissue. 
 
Although some studies have been done to investigate the biological differences between 
healing and normal fibroblasts in skin wounds [59-62], few studies have been done to compare 
these differences in ligaments such as the MCL.  These differences are especially important to 
explore in ligaments in order to restore the original function of the ligament.  Thus, this study 
had two objectives: the first was to determine the functional differences in terms of contraction 
forces between healing and normal MCL fibroblasts; and the second objective was to determine 
the difference in collagen synthesis between healing and normal MCL fibroblasts.  Studying the 
differences between normal and healing MCL fibroblasts as this study proposes would allow for 
the identification of the cellular mechanisms that may contribute to scar tissue formation during 
the healing process.   
 
 
 
4.3 MATERIALS AND METHODS 
 
 
In the right knee of eight rats, a 2-mm gap injury was created in the MCL (IACUC #0210947).  
In the contralateral leg, a sham surgery was done, which involved creating a skin incision, gently 
elevating the MCL, and finally closing the skin incision with sutures.  The sham surgery allowed 
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us to take into account any differences that may have been due to the surgery instead of the 
injury itself.  After 10 days, the rats were sacrificed, and “healing MCLs” from the right knees of 
the rats and “normal MCLs” from the left knees of the rats were harvested.  The granulation 
tissue area of the injured MCLs was clearly marked by the differing matrix composition; the area 
was pinker in color and also much thicker than the rest of the ligament.  Only this area of the 
injured MCL and the 2 mm midsection of the sham-operated MCL were excised for culture 
experiments.  The reason for choosing 10 days is that the healing tissue is in the proliferation 
phase and fibroblasts are abundant [64].   
 
To obtain fibroblasts from the MCLs, each MCL was washed twice with PBS, cut into small 
pieces in aseptic conditions, and then placed in a small Petri dish with 2 mL of Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S; Invitrogen).  Cells from the MCL tissues grew out onto the Petri 
dishes and were then sub-cultured.  The cells were grown as monolayer cultures in DMEM 
supplemented with 10% FBS and 1% P/S on plastic tissue culture dishes in an atmosphere of 5% 
CO2 and 100% humidity at 37oC.  Note that cells from the injured MCLs were considered as 
“healing” fibroblasts, whereas those from sham-operated MCLs were referred to as “normal” 
fibroblasts.  Also, note that healing and normal fibroblasts of the same passage (either 3 or 4) and 
from the same rat were compared for each individual experiment in this study.  Fibroblasts of 
low passage numbers were used in order to maintain the difference in phenotype. 
 
Fibroblast contraction was measured using a multi-station culture force monitor (CFM) 
system that was developed previously in our laboratory [65]. Briefly, semi-conductor strain 
19 
 
  
 
 
gauges were attached to each of four cantilever beams.  A power supply provided 4 V of 
excitation to the strain gauges.  A Labview program tracked the voltage of each cantilever beam 
through a data acquisition card.  Each beam was calibrated by adding pieces of wire with known 
weights and recording the change in voltage.  These weights were converted into force 
measurements and a linear trendline was drawn using MS Excel.  The accuracy of the CFM 
system is 0.1 dynes. 
 
To measure cell contraction forces, fibroblast populated collagen gels (FPCGs) were attached 
to the CFM system.  A collagen solution was made from the combination of 0.1 M NaOH, 10x 
PBS, and collagen type I (Cohesion Technologies Inc.) in a ratio of 1:1:8.  Fibroblasts were 
trypsinized from Petri dishes, centrifuged, and resuspended in growth medium.  For each MCL 
FPCG, 1.5 x 106 cells were incorporated into 3 mL of collagen solution with growth medium.  
The FPCG solution was pipetted into a silicone dish of dimensions 9 cm x 3 cm x 1 cm with a 
porous vyon bar at each end and allowed to polymerize for about one hour at 37°C.  The FPCG 
solution attached to the vyon bars as it polymerized.  Following incubation, 7 mL of growth 
medium was added to each silicone dish.  The vyon bar at one end was connected to the silicone 
dish and thus was stationary, while the vyon bar at the other end connected to the cantilever 
beam using a wire connection.  After the FPCGs were attached to the CFM system, contraction 
forces were monitored for up to 48 hours.  Every 10 min, 100 data points were collected in a 10 
sec period using the Labview program.  These 100 data points were averaged and the average 
value was used as the force measurement for that time. 
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To promote collagen synthesis in the FPCGs, ascorbic acid, at a concentration of 0.06 
mg/mL, was added to the 7 mL of medium around each FPCG.  Samples of medium were 
collected during the contraction experiments at 20 hours to measure levels of collagen synthesis 
using the Procollagen Type I C-Peptide EIA Kit (Takara, Japan), which assesses collagen 
production by a standard sandwich ELISA method for procollagen type I carboxy-terminal 
peptide (PIP).  The detection of collagen synthesis using this method was first reported by 
Taubman et al., using polyclonal antibodies [66].  Briefly, in a 96-well plate that was pre-coated 
with a monoclonal antibody, an antibody-peroxidase conjugate solution, which is a secondary 
monoclonal antibody, was added to the appropriate wells. Either standard or sample was added 
to each well containing conjugate solution within 5 minutes. After 3 hours of incubation at 37°C, 
the sample solution was removed, and the wells were washed 4 times with PBS. Next, a 
Substrate Solution was added to each well, and the plate was incubated at room temperature. 
After 15 minutes, a Stop Solution of 1 M H2SO4 was mixed into each well.  The color intensity 
of the solution in each well was proportional to the amount of PIP in the sample.  The 
absorbance of the samples was read on a plate reader at 450 nm.  
 
To ensure that the differences in contraction forces were not due to differences in cell 
numbers, an MTT Assay was performed on FPCGs in 6-well plates to assess cell viability.  This 
assay measures the mitochondrial activity of cells to assess cell growth.  Cells were mixed with a 
collagen solution as mentioned previously and plated in 6-well plates at a cell number of 10 x 
104 cells per well overnight.  To each well, 200 µL of MTT (tetrazolium salt 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) solution (5 mg/mL) was added and the 
plate was incubated for 3 hours at 37°C.  The plate was then centrifuged at 1900 RPM for 5 min.  
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The supernatant was extracted, and the insoluble product was dissolved with the addition of 1 
mL extraction buffer (15% w/v Lauryl Sulfate (SDS), 44% v/v Dimethyl Formamide (DMF), 
41% v/v H2O).  The plate was incubated overnight at 37°C and absorbance of the samples was 
read at 550 nm.  Cell viability was measured at 24 and 48 hours. 
 
An unpaired t-test was used to determine whether a statistical difference existed in 
contraction forces between healing and normal fibroblasts.  A paired t-test was used to determine 
whether there was a significant difference in collagen synthesis between healing and normal 
fibroblasts.  In both analyses, the significance level was set at 0.05. 
 
 
 
4.4 RESULTS 
 
 
When grown in tissue culture dishes, healing and normal MCL fibroblasts were seen to have a 
similar morphology (Fig 1).   
 
 
A B
 
 
 
 
 
 
 
 
 
 
 
Figure 1  The morphology of healing (A) and normal (B) fibroblasts was similar.  They look 
similar in culture under the same experimental conditions. 
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Using the CFM system, healing fibroblasts were found to have larger contraction forces than 
their normal counterparts.  Tracking the forces every 10 min, healing fibroblasts were seen to 
reach maximum contraction forces around 25 hours (Fig 2).  Although it appears that the 
contraction forces decrease after reaching this maximum force, we believe that this occurs 
because we do not replace the medium around the FPCGs during the course of the experiment.  
In comparing contraction forces between healing and normal fibroblasts every hour, it was found 
that healing fibroblasts produce a significantly greater force of contraction than normal 
fibroblasts at 15 hours of contraction (Fig 3) (p<0.05).  The differences in contraction forces 
remain significant as is evident at 20 hours of contraction.  Specifically, the healing fibroblasts 
showed 1.58 and 1.69 times greater contraction forces than their normal counterparts at 15 and 
20 hours. 
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Figure 2 Fibroblast contraction tracked from the CFM system.  Healing fibroblasts produced a 
greater contraction than normal fibroblasts. 
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Figure 3 Contraction of healing and normal fibroblasts.  Beginning at 15 hours, healing 
fibroblasts produced a significantly greater contraction than normal fibroblasts. Similar results 
were obtained at 20 hours.  
 
Cell number was not a contributor to the differences that were seen.  The difference in cell 
numbers between collagen gels with healing cells and those with normal fibroblasts was not 
significant at 24 hours (Fig 4).  Although the difference in healing and normal fibroblast cell 
numbers did reach significance at 48 hours (p < 0.05), we only compared contraction forces at 
10, 15, and 20 hours, so this did not affect our findings.  Furthermore, the healing fibroblasts 
consistently produced significantly more collagen than normal fibroblasts in all experiments 
(Fig. 5) (p < 0.05).  On average, healing fibroblasts produced 10% more collagen than their 
normal counterparts. 
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Figure 4  Proliferation of healing and normal fibroblasts in collagen gels.  Proliferation of 
healing fibroblasts was significantly faster than normal fibroblasts at 48 hours but not at 24 
hours. 
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Figure 5  Collagen production by healing and normal fibroblasts.  Medium was collected after 
20 hours of contraction to assay collagen levels.  It was found that healing fibroblasts 
consistently produced more collagen than normal counterparts. 
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4.5 DISCUSSION 
 
 
This study demonstrated that healing fibroblasts generate greater forces of contraction and 
produce more collagen than their normal counterparts.  Healing MCL fibroblasts are surrounded 
by a different environment than those from a normal ligament and therefore, it would be 
expected for them to have differential expression.  They need to regenerate the matrix around 
them and pull the wound closed, so they need the ability to have increased collagen synthesis as 
well as increased contractile forces.  The increased contractile forces may also influence the 
amount of collagen produced since contracting fibroblasts in stressed, anchored collagen gels 
have been shown to produce more collagen than the more relaxed fibroblasts that are found in 
unstressed, free floating gels [54]. 
 
Differences between healing and normal MCL fibroblasts were revealed not only on a 
functional level in this study, but also on a protein level.  Healing fibroblasts have a different 
function than normal fibroblasts and therefore, must also express different levels of proteins in 
order to fulfill this function.  Fibroblasts from keloids generate higher levels of contraction [58] 
and have elevated collagen synthesis than normal fibroblasts [59].  Also, hypertrophic scar 
fibroblasts secrete more type I collagen than normal dermal fibroblasts [60].  Thus, since this 
phenomenon occurs in skin following injury, similar events may occur in ligaments following 
rupture.  Fibroblasts contributing to the formation of scar tissue in the MCL must also be more 
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contractile and produce greater amounts of collagen.  It is important to identify these differences 
in order to focus on the aspects that are most important in improving the wound healing process. 
 
It should be noted that the differences found in this study were not due to changes in cell 
number.  It was found that there was not a significant difference in cell number between healing 
and normal fibroblasts at 24 hours.  Healing fibroblasts produced significantly greater forces of 
contraction much before 24 hours and reached maximum contraction forces around 25 hours.  
Further, the medium was sampled to assess collagen type I secretion levels before 24 hours.   
 
There are also a few limitations in this study that are important to note.  The fibroblasts used 
for these experiments were of passages 3 or 4.  Although the healing fibroblasts most likely did 
lose their phenotype a little with each passage, differences between the healing and normal 
fibroblasts in collagen synthesis and contractile forces were still evident.  The differences that 
were noted would most likely be even greater at lower passage numbers, and probably not as 
evident with increasing passage numbers.  Also note that this study investigated the differences 
between healing and normal fibroblasts at only one time point after the injury was made, after 10 
days.  At 5 days post-injury, the ligament may still be in an inflammatory stage and therefore, it 
may be harder to isolate the fibroblasts from the other cell populations.  Further, several weeks 
post-injury, the healing phase may slow down because not as much remodeling needs to be done.  
Thus, the differences may not be as pronounced.  A future study tracking the changes in levels of 
collagen synthesis and fibroblast contraction that occur over the course of wound healing in the 
MCL would be interesting to look into.  Further, it would be interesting to look at the differences 
in other collagen types, such as type III, which is known to be elevated in healing tissue [67]. 
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Thus, this study showed that healing fibroblasts produce greater contractile forces and more 
collagen than normal fibroblasts, both of which may be potential contributors to the scar tissue 
that forms following rupture of the MCL.  Therefore, regulating these factors may lead to 
reduced scar formation in healing ligaments such as the MCL. 
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5.0  THE EFFECT OF TGF-β1 AND TGF-β3 ON HEALING RAT MCL 
FIBROBLASTS 
 
 
 
5.1 ABSTRACT 
 
 
TGF-β1 and TGF-β3 are important regulators of many functions during wound healing.  In vitro, 
they have both been found to increase cellular contraction, which contributes to the formation of 
scar tissue.  TGF-β1 and TGF-β3 have also been found to increase α-SMA expression.  Cellular 
contraction may be regulated by the presence of α-SMA at the wound site.  Interestingly, while 
TGF-β1 increased scarring in a rat skin wound, TGF-β3 reduced it.  Using an FPCG model, it 
was found that TGF-β1 and TGF-β3 both increased fibroblast contraction and α-SMA protein 
expression of healing MCL fibroblasts, with TGF-β3 acting to a lesser extent.  TGF-β1 and TGF-
β3 increased fibroblast contraction 3.1 and 2.7 fold over untreated controls.  Further, α-SMA 
protein expression was increased 1.8 and 1.3 fold by TGF-β1 and TGF-β3, respectively, 
compared to untreated controls.  Thus, TGF-β1 and TGF-β3 have differential effects on healing 
MCL fibroblasts.  Differential regulation of these growth factors during ligament healing may 
improve the quality of a healed ligament.   
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5.2 INTRODUCTION 
 
 
Growth factors (e.g. TGF-β and PDGF) have been investigated as potential biological therapies 
to reduce scar tissue formation [21].  Since expression of TGF-β is increased in healing tissue as 
compared to normal tissue [61], its regulation may be useful in restoring structural and 
mechanical properties of injured ligaments.  In wounded fetal tissue where scarring does not 
occur, the inflammatory response is greatly reduced, if not absent [25, 29, 68].  Furthermore, 
fetal wounds are characterized by a low concentration of TGF-β1 and a high concentration of 
TGF-β3 [27, 28].  In rat skin wounds, addition of TGF-β3 or neutralization of TGF-β1 was 
shown to decrease the formation of scar tissue [14].  Also, antisense oligonucleotides to TGF-β1 
were found to significantly inhibit the formation of scar tissue in the eye of a mouse [46]. 
 
Previous studies have shown that the addition of either TGF-β1 or TGF-β3 to a fibroblast-
populated collagen gel (FPCG) increases fibroblast contraction [11, 12], although to different 
extents.  At the same dosages, TGF-β1 increases fibroblast contraction more than TGF-β3.  
Individually, TGF-β1 and TGF-β3 act in similar dose-dependent manners on fibroblast 
contraction.  They have both also been shown to increase protein expression of α-SMA [15-18, 
52].  The increased contraction may be mediated by the increased presence of α-SMA.  
Electroinjection of an antibody to α-SMA inhibited contraction in gingival and periodontal 
ligament fibroblasts [69].  Further, as the expression of α-SMA signifies the appearance of 
myofibroblasts, which are known to generate large contraction forces in healing tissue [15-18].  
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Interestingly, inhibition of α-SMA expression in rat skin wounds using vanadate resulted in less 
scar formation [53]. 
 
TGF-β1 and TGF-β3 regulate many cell functions, such as cell contraction and collagen 
synthesis during the wound healing process [10, 11, 18, 29, 47].  Their differential effects on 
levels of cell contraction may be an important factor in the differential effect they have on the 
formation of scar tissue.  It is also important to investigate the potential causes of their 
differential contractile ability in order to improve ligament healing.  Therefore, the objective of 
this study was to look into the effects of TGF-β1 and TGF-β3 on cellular contraction and α-SMA 
expression.  Regulation of α-SMA may decrease the level of fibroblast contraction seen at the 
wound site and thus improve the quality of the healed ligament. 
 
 
 
5.3 MATERIALS AND METHODS 
 
 
Healing fibroblasts were obtained from the MCLs in the right knees of eight Sprague-Dawley 
rats.  A 2-mm gap injury was created in the MCL and allowed to heal for 10 days, after which, 
the rats were sacrificed and the MCLs were excised and placed in cell culture medium.  MCLs 
were harvested after 10 days because the healing tissue was considered to be in the proliferation 
phase and at that time fibroblasts are abundant [64].  To obtain fibroblasts, MCLs were 
individually washed twice with PBS and then minced into small pieces in 60 x 15 mm 
polystyrene tissue culture dishes.  Subsequently, 2 mL of DMEM with 10% FBS and 1% P/S 
was added to each dish and the dishes were maintained in an atmosphere of 5% CO2 and 100% 
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humidity at 37°C.  Once fibroblasts reached confluence, they were sub-cultured four times for all 
experiments. 
 
Contractile forces of healing fibroblasts were measured using the multi-station CFM system 
described in Chapter 4.  The collagen solution was prepared by combining 0.1 M NaOH, 10x 
PBS, and collagen type I in a ratio of 1:1:8.  Fibroblasts from confluent Petri dishes were 
trypsinized and then centrifuged for 5 min at 1000 rpm.  The cell pellet was resuspended in AIM-
V medium (Invitrogen), a serum-free medium to a concentration of 50 x 104 cells/mL.  Each 
FPCG was created by mixing 3 mL of cell solution and 5 mL of collagen solution and adding 
this FPCG solution into a silicone dish around two porous vyon bars.  The silicone dishes were 
incubated at 37°C for one hour as the FPCG solution polymerized.  Solutions of 1 ng/mL TGF-
β1 and 1 ng/mL TGF-β3 were made by adding the appropriate amount of growth factor to AIM-
V medium.  This dosage of TGF-β was chosen based on previous studies by Campbell et al. [12] 
as well as unpublished data from our laboratory.  After polymerization, 7 mL of AIM-V with 
TGF-β1, AIM-V with TGF-β3, or growth factor-free AIM-V medium was added to the 
appropriate FPCGs.  Gels were connected to the CFM system and contraction was tracked for 20 
hours. 
 
To assay α-SMA protein expression, cells were removed from collagen gels after 20 hours of 
contraction using a protocol adapted from Vaughan et al. [42].  Gels were washed twice with 
PBS and then incubated with trypsin for 10 min at 37°C.  Subsequently, collagenase (Sigma 
Aldrich) at a concentration of 3 mg/mL was added to each gel and gels were incubated again for 
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15 min at 37°C.  The reaction was stopped using FBS.  Samples were centrifuged for 10 min at 
1000 rpm and then the cell pellet was resuspended in 100 µL of mammalian protein extraction 
reagent (MPER; Pierce) containing protease inhibitors.  The lysed cell solution was centrifuged 
again for 5 min at 8000 rpm.  The supernatant was extracted and used to assay α-SMA. 
 
A standard Western blotting technique was used to assay α-SMA expression in the protein 
samples.  A BCA Protein assay (Pierce) was used to determine the total protein concentrations of 
the cellular extracts.  Equal amounts of total protein were run on 10% SDS-polyacrylamide gels 
(BioRad, Inc) at a constant voltage of 125 V.  Next, proteins were transferred to a nitrocellulose 
membrane using a standard transfer module (BioRad, Inc) at constant amps of 250 mA for 90 
min.  The membrane was blocked overnight at 4°C, or for 1 hr at room temperature, in a 5% dry 
milk/ PBS-tween 20 solution.  Next, the membrane was probed with a mouse monoclonal anti-α-
SMA antibody (Sigma Aldrich) at a dilution of 1:1333 in a 1% dry milk/ PBS-tween 20 solution, 
followed by a peroxidase-conjugated goat anti-mouse antibody (Jackson ImmunoResearch 
Laboratories Inc.) at a dilution of 1:3333 in a 1% dry milk/ PBS-tween 20 solution.  Bands of α-
SMA were detected using an ECL detection kit (Amersham Biosciences) and then transferred to 
film.  Membranes were re-probed for GAPDH to verify equal protein loading in the gels. 
 
Statistical analysis of differences in contraction forces between the experimental groups was 
done using one-way ANOVA, followed by Bonnferroni’s test for multiple comparisons, with a 
significance level set at 0.05. 
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5.4 RESULTS 
 
 
Both TGF-β1 and TGF-β3, at dosages of 1 ng/mL, produced significantly greater contraction 
forces than untreated controls (Fig 6).  TGF-β1 consistently showed greater contractile forces 
than TGF-β3 in all experiments.  Contraction forces were tracked for a period of 20 hours, at 
which point the forces seemed to level off.  The greatest increase in contraction forces was seen 
between 0 and 10 hours.  The shape of the curves from all three treatment groups was similar.  
Quantitatively, compared to untreated controls, gels treated with TGF-β1 and TGF-β3 showed 
3.1 and 2.6 fold greater contraction forces, respectively, at 20 hours (Fig 7).  Differences 
between both treatment groups and the control were significant.  Although gels treated with 
TGF-β1 consistently showed greater contractile forces than gels treated with TGF-β3 in all 
experiments, the difference did not reach statistical significance. 
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Figure 6  A representative graph of contraction force data tracked from the CFM system.  TGF-
β1 showed greater contractile forces than both TGF-β3 and the untreated control.  The breaks in 
the No TGF-β curve were probably due to a disturbance in the voltage readings of the CFM 
system. 
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Figure 7  Fibroblast contraction due to TGF-β1 and TGF-β3 treatment.  Both TGF-β1 and TGF-
β3 significantly induced greater contraction than the untreated fibroblasts at 20 hours after gel 
contraction.  Although TGF-β1 consistently produced greater forces than TGF-β3 in five 
independent experiments, the difference did not reach statistical significance.   
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Further, differential α-SMA protein expression was seen between control gels, those treated 
with TGF-β1, and those treated with TGF-β3.  TGF-β1 induced maximal expression of α-SMA 
among the experimental groups—greater than both TGF-β3 and controls (Fig 8).  In comparing 
the three groups, TGF-β1 and TGF-β3 induced 1.75 and 1.27 fold more α-SMA than controls, 
respectively (Fig 9).  The greatest increase in levels of α-SMA correlated with the greatest 
increase in forces of contraction seen by treatment with TGF-β1.  Similarly, TGF-β3 had greater 
α-SMA expression and showed greater contraction than untreated controls. 
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Figure 8  A representative Western blot result of α-SMA protein expression.  Fibroblasts treated 
with TGF-β1 and TGF-β3 expressed higher levels of α-SMA protein than untreated fibroblasts; 
moreover, TGF-β1 consistently induced higher α-SMA protein expression than TGF-β3 in five 
separate experiments.  
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Figure 9  Analysis of Western blot results.  TGF-β1 and TGF-β3 consistently produced a higher 
level of α-SMA than untreated controls.  However, only differences between TGF-β1 and 
untreated controls reached statistical significance.  TGF-β1 also consistently expressed more α-
SMA than TGF-β3 in all experiments.  Data was first normalized to the density of GAPDH 
bands and then to the density of the untreated controls. 
 
 
 
5.5 DISCUSSION 
 
 
The results of this study showed that TGF-β1 and TGF-β3 produced greater contractile forces 
than untreated controls.  Although previous studies have differed in their reports of whether 
TGF-β1 or TGF-β3 has a stronger effect [11, 12, 18, 47], this study showed that TGF-β1 
produced greater contraction forces than TGF-β3.  Further, it was found that TGF-β1 induced 
more α-SMA than TGF-β3 and controls, which correlates to the contraction data tracked with the 
CFM system.  These results are interesting because although there was a difference in α-SMA 
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expression between TGF-β1 and TGF-β3 treatment, there was not a large difference in 
contraction forces between these treatment groups.  A possible explanation for this difference is 
that TGF-β3 causes faster migration of fibroblasts than TGF-β1 [48] and therefore, the “more 
tractional forces” generated by TGF-β3 treatment are moderately smaller than those “more 
contractile forces” generated by TGF-β1 treatment. 
 
Previous studies have shown that TGF-β1 and TGF-β3 increase α-SMA expression [15-19], 
which may indicate differentiation of fibroblasts into myofibroblasts.  Myofibroblasts are marked 
by higher levels of α-SMA expression and have also been shown to cause greater contraction in 
healing tissue [20].  These specialized cells are found only transiently in the wound site [30].  
Thus, this study may indicate that TGF-β1 and TGF-β3 cause differentiation of fibroblasts into 
myofibroblasts to different extents.  The induction of α-SMA expression also increases the 
contractile forces produced.  In rat skin wounds, TGF-β1 was found to increase scar formation, 
whereas TGF-β3 actually reduced scarring [14].  Thus, the differential contraction forces and α-
SMA expression seen in this study may explain this differential healing response.  Therefore, α-
SMA expression as well as contractile forces needs to be regulated in order to reduce ligament 
scarring. 
 
A major difference between this study and previous studies is that this study was able to 
quantify the forces of fibroblast contraction in response to TGF-β treatment using the CFM 
system.  Many previous studies only showed qualitative, visual differences in gel areas.  In 
addition, the FPCGs in this study were under tension and not free-floating, which is closer to the 
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in vivo situation of ligaments.  Another advantage of the CFM system is that it can reveal the 
pattern of contraction forces of the FPCG.   
 
There are a few limitations in this study.  The CFM system is accurate to 0.1 dynes, which 
allows us to track very small changes in contraction forces.  However, this also makes the system 
extremely sensitive.  Therefore, on occasion, there are breaks in the curves from the CFM 
system, as seen in Fig 6.  We believe that these are due to jumps in the voltage being sent to each 
beam, which may come from outside disturbances in the lab environment.  However, because the 
general trends of the curves seem uninterrupted, these breaks do not change our results.  Another 
limitation is that we only investigated one dosage of growth factor.  It would be interesting to 
look into different dosages of TGF-β1 and TGF-β3, as both isoforms have been shown to act in a 
dosage-dependent manner [11], where the relationship between contraction and dosage may be 
direct at low dosages but after a maximum effect is reached, the relationship becomes indirect 
and higher dosages induce smaller increases in contraction.  Thus, the differential effect that 
TGF-β3 and TGF-β1 have on scar formation may be due to the levels of each growth factor 
present in the wound site.  Also, since TGF-β1 and TGF-β3 differentially regulate scar formation 
in skin wounds and are present together at the wound site, their effect in combination at the 
appropriate ratios on α-SMA expression and fibroblast contraction should be investigated.   
 
The results of this study suggest that regulating the levels of TGF-β1 and TGF-β3 may be 
important in improving ligament scarring after injury.  TGF-β1 and TGF-β3 were both found to 
increase fibroblast contraction and α-SMA expression, although to different extents.  These are 
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two factors that have a large influence on the formation of scar tissue.  Therefore, down-
regulating the ratio of TGF-β1 to TGF-β3 may help to decrease scar formation.   
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6.0  THE EFFECT OF GEL TENSION ON α-SMA EXPRESSION IN NORMAL RAT 
MCL FIBROBLASTS 
 
 
 
6.1 ABSTRACT 
 
 
There is an increase in tension in the matrix during wound healing.  Previous studies have 
correlated the presence of tension and α-SMA in the matrix qualitatively by comparing tensioned 
and completely untensioned gels.  The increase in expression of α-SMA at the wound site may 
signify the differentiation of fibroblasts into myofibroblasts.  This study quantitatively altered the 
amount of tension in collagen gels populated with ligament fibroblasts and then assessed the 
amount of α-SMA expression.  It was found that α-SMA expression and tension in the matrix 
were directly related: in FPCGs that were relaxed after 5 hours of tension, there was 69% lower 
α-SMA expression than those subjected to 20 hours of tension.  A decrease in tension in the 
matrix caused a decrease in the expression levels of α-SMA protein.  Therefore, decreasing α-
SMA expression by easing the amount of tension in the wound healing matrix may help to 
decrease scarring by reducing myofibroblast differentiation. 
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6.2 INTRODUCTION 
 
 
Myofibroblasts are specialized cells that have properties of both fibroblasts and smooth muscle 
cells [8, 30, 52].  Their differentiation from fibroblasts has been associated with an increase in 
expression of α-SMA, a marker and contractile component of the cells [8, 23, 41, 70, 71].  It has 
been hypothesized in several studies that an increase in α-SMA expression also increases 
contraction of the cells [30, 40, 69].  A previous study showed that electroinjection of an 
antibody to α-SMA into gingival fibroblasts decreased contraction by 93% [69].   
 
During wound healing, injured tissue is subjected to greater amounts of tension.  The process 
of contraction in tissues that are tensioned is due to the activity of cells trying to move through 
the collagen matrix.  The cells spread and elongate themselves [55], which is contrary to smooth 
muscle contraction, and then create tractional forces throughout the entangled collagen fibril 
network [72].  This then creates intracellular tension in the matrix.  Extracellular tension is 
created by anchoring the matrix to a surface.  In a free floating gel, the matrix is mechanically 
relaxed extracellularly.  However, in an anchored gel, the matrix remains stressed extracellularly. 
 
A previous in vitro study compared tension to α-SMA expression by comparing floating 
collagen gels to anchored collagen gels, matrices with low vs. high tension, respectively [19].  It 
was found that after adding 10 ng/mL TGF-β1 to each gel, there was little difference in α-SMA 
expression in the floating gels.  However, there was a 3-fold increase in α-SMA protein 
expression in the anchored matrices [19].  Further, the deletion of TGF-β1-induced α-SMA by 
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incubation with an antibody did not increase α-SMA protein levels in cells on any substrate.  In 
addition, when mechanical force acted on cardiac fibroblasts that had low basal levels of α-
SMA, expression was increased up to 2 fold [57].  In vivo, when tension was increased in a skin 
wound by splinting it, α-SMA expression was increased compared to untensioned controls [20].   
 
As there is tension in both the skin and the heart, there is also tension present in ligaments.  
This study looked at the effect of matrix tension on α-SMA expression of normal MCL 
fibroblasts in collagen gels using a dynamic CFM (DCFM) system, which quantitatively altered 
tension in a collagen gel matrix.  Since α-SMA is related to fibroblast contraction, reducing 
tension in the matrix may decrease contraction forces in the matrix and thereby reduce ligament 
scarring.   
 
 
 
6.3 MATERIALS AND METHODS 
 
 
Normal fibroblasts were obtained from MCLs in the left knees of eight Sprague-Dawley rats.  
MCLs were undermined by a surgeon and then the skin on top of them was sutured.  After 10 
days, the MCLs were excised and harvested.  Ligaments were washed twice with PBS, cut into 
small pieces in a 60 x 15 mm polystyrene tissue culture dish, and then covered with DMEM 
containing 10% FBS and 1% P/S.  Fibroblasts were maintained in this growth medium at 37ºC, 
in an atmosphere of 5% CO2 and 100% humidity, and were sub-cultured to passages of four or 
less for use in experiments. 
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Protein expression of α-SMA was measured from FPCGs that were attached to a dynamic 
culture force monitor (DCFM) system.  This system is a modification to the CFM system 
described in Chapter 4.  The DCFM allows for the adjustment of gel tension during the course of 
the experiment.  While one vyon bar still attaches to the cantilever beam, the second vyon bar 
attaches to a metal block that can be moved manually back and forth to increase or decrease 
tension in the gel (Fig 10).   
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Figure 10 Illustration of dynamic culture force monitor (DCFM) system.  The DCFM system 
can control the amount of tension in the collagen matrix.  The FPCG is anchored by a vyon bar 
on each side.  The tension controller attaches to the vyon bar on the right and can be moved in 
the direction of arrow A to reduce tension levels in the collagen matrix.   
 
 
FPCGs were created using a collagen solution that was made by combining type I collagen, 
0.1 M NaOH, and 10x PBS in a ratio of 8:1:1.  Normal MCL fibroblasts were trypsinized from 
Petri dishes and centrifuged for 5 min at 1100 rpm.  The cell pellet was resuspended in growth 
medium at a density of 50 x 104 cells/mL.  Next, 3 mL of the cell solution was added to 5 mL of 
44 
 
  
 
 
collagen solution for each gel and the mixture was pipetted onto the two vyon bars in individual 
silicone dishes.  After 1 hour of incubation at 37°C, gels were polymerized, 7 mL of growth 
medium was added to each gel, and FPCGs were attached to the DCFM system.  Voltages were 
tracked using a Labview program as with the CFM system.  After 5 hours of contraction, tension 
was decreased in the relaxed group of gels by moving the vyon bar attached to the tension 
controller towards the cantilever beam and decreasing the voltage measurements to those at the 
beginning of the experiment. 
 
Cells were removed from FPCGs after 20 hours of attachment to the DCFM using a protocol 
adapted from a previous study  [42].  FPCGs were washed twice with 1x PBS and then 
trypsinized and incubated at 37ºC for 10 min.  Following, 1 mL of collagenase was added to each 
gel and the gels were incubated again at 37ºC for 15 min.  The reaction was stopped with FBS.  
The cell solution was centrifuged for 10 min at 1100 rpm.  The cell pellet was then resuspended 
in 100µl of MPER containing protease inhibitors.  The lysed cell solution was centrifuged for 5 
min at 8000 rpm in a microcentrifuge.  The supernatant was extracted and used to assay α-SMA 
protein expression. 
 
A standard Western blotting technique was used to determine α-SMA protein expression.  A 
BCA protein assay was run on all samples to determine total cellular protein concentration.  
Equal amounts of total protein were run on 10% Tris-HCl polyacrylamide gels using gel 
electrophoresis at a constant voltage of 125 V.  Protein was transferred to a nitrocellulose 
membrane using a standard BioRad transfer module at 250 mA for 90 min.  The membrane was 
blocked overnight at 4ºC, or for 1 hour at room temperature, in a 5% dry milk/ PBS-tween 20 
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solution.  A mouse monoclonal anti-α-SMA antibody was used to first probe α-SMA at a dilution 
of 1:1333 in 1% dry milk/ PBS-tween 20, followed by a peroxidase-conjugated goat anti-mouse 
antibody at a dilution of 1:3333 in a 1% dry milk/ PBS-tween 20 solution.  Bands of α-SMA 
were exposed using an ECL detection kit and then transferred to film.  Membranes were re-
probed for GAPDH to ensure equal loading. 
 
A paired t-test was used to determine whether a statistical difference existed in α-SMA 
expression between tensioned and relaxed gels in normal fibroblasts.  The significance level was 
set at 0.05. 
 
 
 
6.4 RESULTS 
 
 
Contraction forces were tracked for 20 hours for all FPCGs (Fig 11).  The average difference in 
contraction forces between tensioned and relaxed gels at 20 hours was consistently about 50 
dynes for all five experiments.   
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Figure 11 A representative graph of gel contraction from the DCFM.  The relaxed gels were 
released at 5 hours to their starting voltage reading and then allowed to continue contracting.  
Tensioned gels produced greater maximal contraction forces as compared their relaxed 
counterparts. 
 
 
Western blotting showed that α-SMA expression was less in relaxed samples as compared to 
tensioned samples.  Bands of α-SMA were thinner and less dense in the relaxed samples.  
Analysis of the bands of α-SMA revealed that relaxed gels had 69% less α-SMA expression 
compared to the control tensioned gels.  Therefore, these results suggest that tension and α-SMA 
expression is correlated: decreasing tension in the matrix also decreased α-SMA expression. 
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Figure 12 A representative Western blot result of α-SMA protein expression. The bands from 
tensioned gels were larger than those of the relaxed gels. 
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Figure 13 Bar graph of Western blot analysis.  The relaxed gels consistently expressed less α-
SMA protein than the tensioned gels.  On average, α-SMA protein in relaxed gels was 69% of 
that of tensioned gels. 
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6.5 DISCUSSION 
 
 
The results of this study revealed that α-SMA expression decreased with decreased tension.  
When gels were relaxed at 5 hours of contraction, they showed lower expression of α-SMA 
expression after 20 hours of contraction compared to gels that were tensioned for 20 hours.  The 
average contraction forces at 20 hours of relaxed gels were about 50 dynes less than tensioned 
gels.  An important factor of this study was that only intracellular tension was regulated.  From 
the contraction curve produced by the DCFM system, it is apparent that after the gel was 
released, the cells still produced contractile forces and re-created gel tension.  Increased 
expression of α-SMA is linked to the differentiation of fibroblasts into myofibroblasts [17, 19, 
30, 41, 52, 70].  Myofibroblasts are transiently present during wound healing [30, 40, 41, 51].  
However, their presence has a large impact on the outcome of the healing process, as they have 
been implicated in the formation of scar tissue [53].  With the lack of α-SMA, the myofibroblast 
phenotype disappeared and rat skin wounds healed properly without scarring [53].  The presence 
of α-SMA contributes to the increased contractile ability of myofibroblasts [31].  Excessive 
contraction forces are an important factor in scar tissue formation [8, 9].  At the wound site, the 
increase in contraction due to wound closure increases tension in the matrix [16], which may 
cause differentiation of fibroblasts into myofibroblasts and further enhance the expression of α-
SMA. 
 
Note that there are a few limitations in this study.  First, the difference in contraction forces 
between the tensioned and relaxed gels was about 50 dynes.  This difference in force is not a 
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large amount, as there were 1.5 million cells in each gel, which gives a force difference of about 
0.33 nN/cell.  Therefore, the effect on each cell of the matrix relaxation was very small.  Further, 
this study only released tension in the matrix at one time point in one amount and the gels were 
allowed to continue to contract and regenerate the tension after this.  Future studies should look 
at a dosage response, where tension is released at different levels and α-SMA expression is 
determined.  This would allow a correlation to be drawn between α-SMA expression and tension 
levels in the collagen matrix.  In addition, this study utilized normal fibroblasts instead of healing 
fibroblasts.  The DCFM device used in this study is novel and so the effect of tension on normal 
fibroblasts was investigated first.  This system can precisely control gel tension and can thus 
manipulate cell contraction.  Releasing the amount of tension in the gel can also change the 
compliance of the matrix that the cells are in.  Now seeing the effect of tension on α-SMA in 
normal fibroblasts, future studies should investigate the effect on healing fibroblasts.   
 
This study showed that decreasing tension in a collagen matrix decreased α-SMA expression.  
Therefore, the amount of tension in the wound healing matrix may be an important factor in the 
formation of scar tissue.  In the future, levels of collagen synthesis should be assessed.  Previous 
studies have directly correlated tension and collagen synthesis [54].  Both contraction and 
collagen synthesis may impact scar formation [7].  Thus, relaxing the tension in the matrix would 
decrease expression of α-SMA and reduce scarring at the wound site. 
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7.0  SUMMARY AND FUTURE DIRECTIONS 
 
 
In summary, this study shows that healing and normal fibroblasts from MCLs exhibit differential 
abilities of contraction and collagen type I production.  When TGF-β1 and TGF-β3 were added 
to healing fibroblasts seeded in collagen gels, both were found to increase contraction forces 
compared to untreated controls—but, TGF-β1 consistently produced higher forces than TGF-β3.  
In addition, TGF-β1 induced greater α-SMA protein expression than both TGF-β3 and untreated 
controls.  Finally, this study showed that normal fibroblasts in relaxed collagen gels had 
decreased α-SMA protein expression compared to tensioned collagen gels. 
 
The findings of this thesis highlight the importance of using healing fibroblasts instead of 
normal fibroblasts in studying the cellular mechanisms involved in scar formation during 
ligament healing, as they are functionally different.  Fetal wounds are characterized by an 
increased presence of TGF-β3 and heal without scar formation, unlike adult wounds.  TGF-β1 
and TGF-β3 increase contraction and α-SMA expression, which are both important factors in 
wound healing, to different extents.  Thus, regulating the relative expression levels of TGF-β1 
and TGF-β3 may result in reduced scarring in healing ligaments.  In addition, the effect of 
tension on α-SMA is an important factor in the healing process.  An increase in tension at the 
wound site may increase differentiation of fibroblasts into myofibroblasts and thus, increase scar 
formation.   
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Future studies should look into the effect of TGF-β1 and TGF-β3 at different dosages and in 
combination on cell contraction, collagen secretion, and α-SMA expression.  Previous studies 
have shown that TGF-β1 and TGF-β3 differentially regulate scar formation in skin wounds and 
these three factors are all important in scarring.  Therefore, the application of these growth factor 
isoforms in the appropriate ratios may improve ligament healing.  Further, the effect of tension 
on α-SMA expression should be assessed in healing fibroblasts.  Tension should be 
quantitatively altered at different levels so that a correlation between tension levels in the matrix 
and α-SMA expression can be obtained.  Lastly, the application of these factors should be tested 
in vivo, e.g., by injection of TGF-β3 or an antibody to TGF-β1 to the wound site or 
immobilization of the injured joint to decrease tension at the wound site, to investigate their 
effect on ligament scar formation in an animal model.   
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APPENDIX A 
 
 
 
EXPERIMENTAL PROTOCOLS 
 
 
 
Harvesting Fibroblasts from Ligament Tissue 
 
1. Place ligament in growth medium at animal facility. 
2. Wash MCL in cell culture hood twice with growth medium. 
3. Mince MCLs into pieces in small Petri dishes. 
4. Add 2 mL to each Petri dish.  MCLs should not be floating. 
5. Incubate at 37°C, 5% CO2, and 100% humidity. 
6. Replace medium every 2-3 days. 
7. Subculture fibroblasts once they are confluent in the Petri dishes. 
 
 
53 
 
  
 
 
Measuring FPCG Contraction with CFM System 
 
 
1. Warm medium and trypsin 
2. Make collagen gel solution: 
a. For 4 gels (mix in 50 mL conical tube): 
i. 2.2 mL of 10X PBS 
ii. 2.5 mL of 0.1 M NaOH 
iii. 17.6 mL collagen stock solution (Vitrogen) 
b. Mix well, store at 4°C until needed 
3. Make Ascorbic Acid solution if necessary 
a. Add 15.50 mg to 20 mL ddH2O 
4. Prepare cells: 
a. Extract media from cell dish 
b. Add 3 mL of trypsin to cells and place in incubator for 3 minutes 
c. Check cells, via light microscope, to ensure that they are unattached 
d. Add 5 mL of growth media (with 10% FBS) to counter the trypsin   
e. Using a pipette, tilt the Petri dish and wash cells to the bottom 
f. Pipette the cells into an appropriate sized conical tube 
g. Centrifuge the cell solution (1000 RPM for 5 minutes) 
h. Set out collagen solution while waiting for the centrifuge 
i. Extract supernatant, leaving the cell pellet and a small amount of solution, try not 
to loose cells 
j. Add a small amount of the medium (growth medium or AIM-V for TGF-β 
experiments) that will be used in the experiment and mix well 
k. Count cells with hemacytometer 
i. Clean and dry hemacytometer 
ii. Place cover slip on hemacytometer 
iii. Obtain 10µL of well mixed cell solution and pipette onto hemacytometer 
iv. Count the four corners and find the total cells per 
mL=(C1+C2+C3+C4)x104/4 (cells/mL)  
l. Dilute cells solution to appropriate density (50 x 104 cells/ mL) 
5. Prepare silicone dishes and gel attachment units to add the FPCG solution 
6. Mix: 
a. 13.2 mL cells to the 22 mL collagen solution 
7. Pipet 8 mL of mixture onto and between vyon bars for each gel 
8. Incubate for 1 hour 
a. While waiting, start CFM setup program on computer 
9. Setup up computer and data acquisition system 
a. Turn on power supply and check excitation voltage with volt meter (this will 
allow strain gages to get to temperature) 
b. Start “Setup” program for CFM 
10. Add 7 mL of appropriate medium (growth medium, AIM-V, or AIM-V with TGF-β1 or 
β3) 
11. Label gels 
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12. Add Ascorbic Acid if testing for collagen synthesis 
13. Attach to CFM and provide initial tension (check by seeing ~ 2-3 mV increase) 
14. Stop “Setup” program and run CFM “Experiment” program 
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Preparation of FPCGs in 6-well Plates 
 
 
1. Warm medium and trypsin 
2. Make collagen gel solution: 
a. For 6 wells: 
i. 1.1 mL of 10X PBS 
ii. 1.3 mL of 0.1 M NaOH 
iii. 9.1 mL collagen stock solution (Vitrogen) 
b. Mix well, store at 4°C until needed 
3. Prepare cells: 
a. Extract media from cell dish 
b. Add 3 mL of trypsin to cells and place in incubator for 3 minutes 
c. Check cells, via light microscope, to ensure that they are unattached 
d. Add 5 mL of growth media to counter the trypsin   
e. Using a pipette, tilt the Petri dish and wash cells to the bottom 
f. Pipette the cells into an appropriate sized conical tube 
g. Centrifuge the cell solution (1000 RPM for 5 minutes) 
h. Set out collagen solution while waiting for the centrifuge 
i. Extract supernatant, leaving the cell pellet and a small amount of solution, try not 
to loose cells 
j. Add a small amount of growth medium and mix well 
k. Count cells with hemacytometer 
i. Clean and dry hemacytometer 
ii. Place cover slip on hemacytometer 
iii. Obtain 10µL of well mixed cell solution and pipette onto hemacytometer 
iv. Count the four corners and find the total cells per 
mL=(C1+C2+C3+C4)x104/4 (cells/mL)  
l. Dilute cells solution to appropriate density (12.5 x 104 cells/ mL) 
4. Prepare silicone dishes and gel attachment units to add the FPCG solution 
5. Mix: 
a. 6.9 mL cells to the 11.5 mL collagen solution 
6. Pipette 1.4 mL of cell-collagen solution into each well 
7. Incubate at 37°C for 1 hour 
8. Add 3 mL medium to each well 
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MTT Assay for Measuring Cell Number in 6-well Plates 
(Adapted from: Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55-63) 
 
 
1. Add 200 µl MTT solution (5 mg/mL) to each FPCG in a 6-well plate 
2. Incubate for 3 hours at 37°C with 5% CO2 and 100% humidity 
3. Centrifuge 6-well plate at 1900 rpm for 5 min 
4. Remove supernatant 
5. Add 2 mL extraction buffer 
a. 15 mL DMF 
b. 14.1 mL ddH2O 
c. 5 g SDS 
6. Incubate overnight 
7. Add 200 µl of each sample to a 96-well plate 
8. Read plate using microplate reader at 550 nm 
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Protein Extraction from FPCGs 
(Adapted from: Vaughan, M.B., E.W. Howard, and J.J. Tomasek. 2000. Transforming growth 
factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp 
Cell Res. 257:180-9) 
 
 
1. Remove growth medium 
2. Rinse twice with 1x PBS at room temp for 10 min 
3. Incubate with 2 mL 0.25% Trypsin and incubate for 10 min at 37°C 
4. Digest with 1 mL 3 mg/mL collagenase (in 130 mM NaCl, 10 mM Ca Acetate, 20 mM 
Hepes, pH 7.2) and incubate for 15 min at 37°C 
5. Add 100 µL of FBS to stop the reaction 
6. Centrifuge the samples for 10 min at 1000 rpm 
7. Make lysis buffer: 
a. 1 mL M-PER + 15µl of protein cocktail 
8. Extract supernatant 
9. Resuspend cell pellet in 100 µl lysis buffer 
10. Centrifuge sample in microcentrifuge for 5 min at 8000 rpm 
11. Collect supernatant 
12. Assay for protein using standard BCA Protein Assay (Pierce) 
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Assaying α-SMA using Western Blot 
 
 
I. Set up gel module: 
1. Make running buffer (100 mL 10 x Tris/Glycine/SDS + 900 mL ddH2O) 
2. Open pre-made gels. 
3. Take off white tape at the bottom of the gel. 
4. Take out the comb from the top of the gel. 
5. Place gel in module and secure it. 
6. Add running buffer to the module such that it covers the top of the gel. 
 
II. Prepare samples and running the gel: 
1. Turn on dry bath heater. 
2. Vortex samples (keep samples on ice).  Spin in minispinner. 
3. Make loading buffer: 
a. Add a ratio of (10 sample buffer: 1 DTT) to an eppendorf tube (make enough to 
add 20 µL to each sample). 
4. Calculate the volume of each sample that would be required to load 10 µg of protein.  
Add that volume of sample to its own eppendorf tube (label tubes accordingly). 
5. Add DI water to each protein sample to give a final volume of 20 µl. 
6. Add 20 µl loading buffer to each sample for a volume ratio of 1 sample: 1 loading. 
7. Heat the sample and loading buffer mixture for 4 minutes at 90 to 100ºC (put on ice 
afterwards). 
8. Spin down the sample tubes via centrifuge for 20 to 30 seconds. 
9. Add 10 µL of the protein standard to the first well. 
10. Add 37 µL of a sample to each well. 
11. Attach the electrodes and run at constant voltage of 125 V for 110 minutes (shut down 
the electrophoresis when the indicating dye nears the bottom of the gel). 
 
III. Transfer of the protein from the gel to the nitrocellulose membrane 
1. Make transfer buffer (100 mL 10x Tris/Glycine, 200 mL Methanol, 700 mL ddH2O) 
2. Place transfer module, 2 sponges, 2 pieces of filter paper, and filter paper-nitrocellulose 
membrane sandwich into a container with transfer buffer. 
3. Pour out the running buffer from the electrophoresis module. 
4. Remove the gel from the module. 
5. Pry the sides of the gel container open. 
6. Carefully cut the top, bottom, and edges of the gel. 
7. Remove the gel and place it (with protein standards on the right) on top of 2 pieces of 
filter paper in the transfer module, which is in the transfer buffer. (Gel should be on gray 
side of module) 
8. Make sure all the bubbles are removed. 
9. Place the nitrocellulose membrane on top of the gel. (Membrane should be on white side 
of module) 
10. Place another 2 pieces of filter paper on top of the membrane and then add the sponge. 
11. Clean the electrophoresis module and fill halfway with transfer buffer. 
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12. Place the transfer module into the electrophoresis module (gray side should be on the 
black side of the electrophoresis module, white side should line up with red side of 
electrophoresis module) and secure it. 
13. Add transfer buffer to the top of the module. 
14. Place in container with ice. 
15. Run at constant amps of 250 mA for 90 minutes. 
 
IV. Binding of the proteins 
1. Rinse the membrane with DI water. 
2. Place the membrane in 5% fat-free milk/PBS-T solution  
a. Shake overnight in the cold room or for 1 hour at room temperature. 
3. Add 15 µL of the primary antibody to 20 mL of 1% fat-free milk/PBS-T. 
4. Add this solution to the membrane and shake for 1.5 hours at room temperature. 
5. Pour off the milk solution and wash the membrane 3 times for 15 minutes with .1% PBS-
T. 
6. Add 3 µL of the secondary antibody to 20 mL of 1% fat-free milk/PBS-T (1 2º AB: 5000 
1% fat-free milk/PBS-T). 
7. Add this solution to the membrane and shake for 1 hour at room temperature 
8. Pour off milk solution and wash the membrane 3 times for 15 minutes with .1% PBS-T. 
 
V. Exposure of the membrane 
1. Make ECL solution (follow kit instructions): 
a. Add 3 mL of solution A into a 15 ml conical tube. 
b. Add 75 µL of solution B to solution A. 
2. Lay out two pieces of saran wrap (bigger than the membrane). 
3. Blot dry the membrane and place it on the center of one of the pieces of saran wrap with 
protein side up (the top left corner should be the cut corner). 
4. Add 3 mL of the ECL solution (from 1) to the membrane and spread it across the 
membrane (ensure that there are no bubbles and that the entire surface is covered). 
5. Let sit for 5 minutes. 
6. Drain off excess ECL by placing the edge of the membrane onto a piece of filter paper. 
7. Place the membrane with the protein side down (top right corner should be the cut 
corner) on top of the other piece of saran wrap. 
8. Wrap the membrane and cut off extreme excess of saran wrap. 
9. Place the wrapped membrane into the film tray with the protein side up (top left corner 
should be the cut corner). 
10. Take the membrane, film, exposure tray, and scissors immediately down to the dark room 
to develop (BST 15th Floor). 
11. In the dark room, cut the film to a size somewhat bigger than the membrane. 
12. Place the film on top of the wrapped membrane (protein side up) and expose for about ~ 
1 min. (time may vary depending on protein concentration, adjust accordingly). 
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APPENDIX B 
 
 
 
DATA ANALYSIS 
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Specific Aim #1: The following graphs represent the contraction forces produced by healing and 
normal fibroblasts in FPCGs connected to the CFM system.  Contraction was tracked for 20 to 
30 hrs.  A total of four experiments were done. 
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Experiment #3: 
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Experiment #4: 
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Analysis of Healing vs. Normal Contraction Data
Healing Fibroblast Contraction Forces (dynes)
Time Expt #1 Expt #2 Expt #3 Expt #4
1 0 3.292 3.216 6.185 4.507 1.048
2.00 8.423 7.049 12.095 21.299 17.926 10.58
3.00 27.628 15.186 32.44 47.19 31.969 18.399
4.00 53.42 21.112 53.677 70.811 48.719 24.163
5.00 67.141 30.175 111.617 80.332 61.256 26.811
6.00 77.969 41.380 87.543 79.396 69.767 30.313
7.00 83.952 46.268 99.37 74.849 83.956 33.859
8.00 90 51.786 111.066 73.749 97.002 38.101
9.00 98.899 57.675 116.535 74.104 110.029 44.178
10.00 107.966 64.749 123.643 76.805 123.845 51.17
11.00 114.677 75.106 128.581 80.973 129.35 58.748
12.00 122.541 87.180 137.132 87.054 144.319 67.962
13.00 131.03 97.425 146.767 94.165 158.551 78.266
14.00 141.29 106.256 155.401 102.202 171.237 88.798
15.00 149.759 116.131 163.36 108.924 181.823 98.976
16.00 157.574 123.881 172.87 116.28 190.904 106.724
17.00 163.462 130.899 192.728 116.843 198.101 114.522
18.00 168.31 136.599 223.166 127.132 205.136 119.985
19.00 171.648 141.030 226.223 148.771 211.86 129.885
19.67 173.923 143.830 225.106 158.628 216.078 135.6
Normal Fibroblast Contraction Forces (dynes)
Time Expt #1 Expt #2 Expt #3 Expt #4
1 7.801 0 12.361 14.681
2.00 10.02 0.668 39.092 18.797
3.00 20.164 1.201 74.418 18.84
4.00 24.470 3.646 102.152 15.373
5.00 34.031 9.896 69.52 9.448
6.00 41.470 28.129 114.67 8.262
7.00 44.406 34.45 111.791 8.652
8.00 49.294 36.196 109.782 10.228
9.00 54.958 38.603 109.23 12.906
10.00 59.901 40.909 110.254 16.196
11.00 67.281 42.393 111.586 22.537
12.00 77.351 48.287 114.504 28.861
13.00 87.270 53.902 117.42 38.589
14.00 93.575 59.828 120.74 45.795
15.00 104.039 65.358 124.706 52.655
16.00 112.026 70.336 128.788 59.428
17.00 119.681 74.184 139.028 65.466
18.00 127.451 64.752 139.753 70.733
19.00 134.814 61.616 135.459 77.134
19.67 138.914 62.683 133.604 81.259
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Analysis of Time Points
10 hrs
Healing (forces in dynes) Average SD
107.966 64.749 123.643 76.805 123.845 51.17 91.363 31.33195
Normal (forces in dynes)
59.901 40.909 110.254 16.196 56.815 39.86709
t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2
Mean 91.363 56.815
Variance 981.6912 1589.385
Observations 6 4
Pooled Variance 1209.576
Hypothesized Me 0
df 8
t Stat 1.538905
P(T<=t) one-tail 0.081194
t Critical one-tail 1.859548
P(T<=t) two-tail 0.162389
t Critical two-tail 2.306004
15 hrs
Healing (forces in dynes) Average SD
149.759 116.131 163.36 108.924 181.823 98.976 136.4955 33.27106
Normal (forces in dynes)
104.039 65.358 124.706 52.655 86.690 33.46461
t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2
Mean 136.4955 86.6895
Variance 1106.963 1119.88
Observations 6 4
Pooled Variance 1111.807
Hypothesized Me 0
df 8
t Stat 2.314049
P(T<=t) one-tail 0.024688
t Critical one-tail 1.859548
P(T<=t) two-tail 0.049376
t Critical two-tail 2.306004
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 19.67 hrs
Healing (forces in dynes) Average SD
173.923 143.830 225.106 158.628 216.078 135.6 175.5275 37.38843
Normal (forces in dynes)
138.914 62.683 133.604 81.259 104.115 37.94548
t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2
Mean 175.5275 104.115
Variance 1397.895 1439.86
Observations 6 4
Pooled Variance 1413.632
Hypothesized Me 0
df 8
t Stat 2.942468
P(T<=t) one-tail 0.00932
t Critical one-tail 1.859548
P(T<=t) two-tail 0.018639
t Critical two-tail 2.306004
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 Collagen Assay Analysis
(OD at 450 nm)
Healing Normal
0.442 0.357
0.2115 0.177
0.336 0.207
1.125 1.073
0.859 0.8125
0.9035 0.8195
Average 0.574333
Normalized to Average Normal OD (at 450 nm)
Healing Normal Difference
0.769588 0.62159 0.147998
0.368253 0.308183 0.06007
0.585026 0.360418 0.224608
1.958793 1.868253 0.09054
1.495647 1.414684 0.080963
1.573128 1.426872 0.146257
Average 1.125073 1 0.125073
SD 0.636233 0.654051 0.060407
t-Test: Paired Two Sample for Means
Variable 1 Variable 2
Mean 1.125073 1
Variance 0.404793 0.427783
Observations 6 6
Pearson Correlatio 0.995997
Hypothesized Mea 0
df 5
t Stat 5.071641
P(T<=t) one-tail 0.001931
t Critical one-tail 2.015048
P(T<=t) two-tail 0.003862
t Critical two-tail 2.570582
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 MTT Assay on Collagen Gels for Proliferation
24 hours (OD at 550 nm)
Healing Normal
0.4125 0.454
0.451 0.4075
0.4265 0.462
0.418 0.476
0.456 0.4075
0.4685 0.5265
Average 0.43875 0.455583
Normalized to 0.963051 1
average Normal OD
SD 0.022814 0.044975
t-Test: Paired Two Sample for Means
Variable 1 Variable 2
Mean 0.43875 0.455583
Variance 0.00052 0.002023
Observations 6 6
Pearson Correlation 0.044954
Hypothesized Mean D 0
df 5
t Stat -0.83287
P(T<=t) one-tail 0.221435
t Critical one-tail 2.015048
P(T<=t) two-tail 0.44287
t Critical two-tail 2.570582
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Specific Aim #2: The following graphs represent the contraction forces produced by FPCGs 
treated with 1 ng/mL TGF-β1, 1 ng/mL TGF-β3, or untreated controls.  The bands below each 
graph are the corresponding results of Western blotting for α-SMA on cells from these FPCGs.  
A total of five experiments were performed. 
 
Experiment #1 (Figure 6 in text): 
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Experiment #2: 
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Experiment #3: 
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Experiment #4: 
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Experiment #5: 
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Contraction Data for TGF-beta
Contraction Forces (dynes)
No TGF-b TGF-b3 TGF-b1
1 45.535 103.170 136.605
2 26.38908 106.9959 108.9041
3 33.04903 90.93652 116.3623
4 43.60297 56.68425 56.72601
5 20.00415 87.57687 102.9363
Average 33.716 89.073 104.307
Normalized to 1.000 2.642 3.094
average No TGF-b
SD 10.94976 19.8412 29.47643
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Column 1 5 168.5804 33.71608 119.8971
Column 2 5 445.3633 89.07267 393.673
Column 3 5 521.5335 104.3067 868.8601
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 13799.1 2 6899.551 14.97266 0.000548 3.885294
Within Groups 5529.721 12 460.8101
Total 19328.82 14
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Bonferroni’s Test 
 
Treatment groups: 
1 = No TGF-β 
2 = TGF-β3 
3 = TGF-β1 
 
Multiple Comparisons
Dependent Variable: Forces
Bonferroni
-55.35665* 13.57661 .005 -93.0925 -17.6208
-70.59069* 13.57661 .001 -108.3265 -32.8549
55.35665* 13.57661 .005 17.6208 93.0925
-15.23403 13.57661 .851 -52.9699 22.5018
70.59069* 13.57661 .001 32.8549 108.3265
15.23403 13.57661 .851 -22.5018 52.9699
(J) Treatment
2.00
3.00
1.00
3.00
1.00
2.00
(I) Treatment
1.00
2.00
3.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Western Blot Analysis for TGF-beta
Density of Western Blot Bands (area x intensity)
A-SMA GAPDH
No TGF-b TGF-b3 TGF-b1 No TGF-b TGF-b3 TGF-b1
1 2.85547 3.572919 4.97821 1 1.708952 1.492764 1.389714
2 2.866338 3.368201 3.851767 2 3.350838 2.362432 1.698144
3 2.296907 2.399679 3.002839 3 4.157937 4.262572 3.388943
4 0.422083 0.488634 0.5522 4 2.062884 2.070082 1.969812
5 5.80289 5.448611 6.253418 5 1.951973 1.701622 2.156108
A-SMA A-SMA
Normalized Relative to GAPDH Normalized Relative to Control
No TGF-b TGF-b3 TGF-b1 No TGF-b TGF-b3 TGF-b1
1 1.67089 2.393492 3.582183 1 1 1.432465 2.143877
2 0.855409 1.425735 2.268222 2 1 1.666728 2.651622
3 0.552415 0.562965 0.886069 3 1 1.019098 1.603992
4 0.204608 0.236046 0.280331 4 1 1.153648 1.370087
5 2.972833 3.20201 2.900326 5 1 1.07709 0.97561
Average 1 1.269806 1.749038
SD 0 0.272714 0.658291
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Column 1 5 5 1 0
Column 2 5 6.349029 1.269806 0.074373
Column 3 5 8.745188 1.749038 0.433347
ANOVA
rce of Varia SS df MS F P-value F crit
Between G 1.439193 2 0.719596 4.251926 0.040186 3.885294
Within Gro 2.030881 12 0.16924
Total 3.470073 14
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Bonferroni’s Test 
Treatment groups: 
1 = No TGF-β 
2 = TGF-β3 
3 = TGF-β1 
 
Multiple Comparisons
Dependent Variable: Density
Bonferroni
-.26981 .26018 .961 -.9930 .4534
-.74904* .26018 .042 -1.4722 -.0259
.26981 .26018 .961 -.4534 .9930
-.47923 .26018 .271 -1.2024 .2439
.74904* .26018 .042 .0259 1.4722
.47923 .26018 .271 -.2439 1.2024
(J) Treatment
2.00
3.00
1.00
3.00
1.00
2.00
(I) Treatment
1.00
2.00
3.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Specific Aim #3: The graphs below represent the contraction forces tracked by the DCFM.  At 5 
hrs, tension was released in the relaxed gels to approximately the starting levels.  The bands 
below each graph represent the corresponding results from Western blotting for α-SMA from the 
tensioned and relaxed gels.  A total of five experiments were performed. 
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Experiment #2 (Figure 11 in text): 
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Experiment #3: 
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Experiment #4: 
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Experiment #5: 
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Contraction Data for Tensioned-Relaxed Experiments
Contraction Forces (dynes)
Tensioned Relaxed
1 138.742 29.645
2 208.574 156.651
3 252.169 168.916
4 189.096 116.495
5 99.317936 26.735
Average 177.580 99.688
Normalized to 1.000 0.561
average Tensioned
forces
SD 59.77053 68.0956
t-Test: Paired Two Sample for Means
Variable 1 Variable 2
Mean 177.57969 99.68847
Variance 3572.5163 4637.011
Observations 5 5
Pearson Correlation 0.9552889
Hypothesized Mean Di 0
df 4
t Stat 8.3675162
P(T<=t) one-tail 0.0005578
t Critical one-tail 2.1318468
P(T<=t) two-tail 0.0011156
t Critical two-tail 2.7764451
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Western Blot Analysis for Tension-Relax Experiments
Density of Western Blot bands (area x intensity)
A-SMA GAPDH
Tension Relax Tension Relax
1 0.415601 0.324324 1 4.697918 4.97569
2 0.508583 0.459844 2 7.428092 7.171498
3 0.325651 0.317562 3 3.121764 4.672022
4 5.936804 3.70447 4 1.412268 2.555504
5 2.295991 1.81594 5 2.627568 2.719313
A-SMA A-SMA
Normalized Relative to GAPDH Normalized Relatvie to Control
Tension Relax Tension Relax
1 0.088465 0.065182 1 1 0.736808
2 0.068467 0.064121 2 1 0.936519
3 0.104316 0.067971 3 1 0.651586
4 4.203737 1.449604 4 1 0.344837
5 0.873808 0.667794 5 1 0.764234
Average 1 0.686797
SD 0 0.217391
t-Test: Paired Two Sample for Means
Variable 1 Variable 2
Mean 1 0.686797
Variance 0 0.047259
Observatio 5 5
Pearson Co #DIV/0!
Hypothesiz 0
df 4
t Stat 3.22159
P(T<=t) one 0.016116
t Critical on 2.131847
P(T<=t) tw 0.032232
t Critical tw 2.776445
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